Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung ...

AI-generated analysis

📈 BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 data for their bispecific drug pumitamig in non-small cell lung cancer.

💉 The investigational PD-L1xVEGF-A bispecific immunomodulator shows robust activity when combined with chemotherapy in first-line treatment.

📊 Confirmed objective response rates reached up to 72.7% in squamous NSCLC and 63.6% in non-squamous NSCLC at the lower dose level.

🎯 High efficacy was observed across all PD-L1 expression subgroups, including patients with low expression (TPS < 1%).

💊 The drug demonstrated a manageable safety profile with a low treatment discontinuation rate and limited high-grade immune-related adverse events.

🌍 The data were presented as an oral session at the 2026 ASCO Annual Meeting in Chicago based on an April 2026 data cut-off.

🏗️ Pumitamig is advancing through a global Phase 3 development program including the pivotal ROSETTA Lung-02 trial currently recruiting for its final part.

🔄 Two additional global Phase 3 trials, ROSETTA Lung-201 and ROSETTA Lung-202, are enrolling patients to compare pumitamig against standard-of-care therapies like durvalumab and pembrolizumab.

💬 Lead investigator Solange Peters stated that targeting the PD-L1 pathway alone is insufficient for durable responses in advanced disease.

🤝 Co-founder Özlem Türeci highlighted the potential of the bispecific molecule to enhance anti-tumor responses by simultaneously targeting PD-L1 and VEGF-A.

🎯 Senior Vice President Anne Kerber emphasized the goal of improving outcomes for patients left behind by current therapies in this challenging disease.

⚠️ Grade 3 or higher treatment-related adverse events occurred in 48.8% of patients, though only one severe bleeding event was recorded.

📉 Discontinuation due to pumitamig-related adverse events was reported in 9.3% of the patients studied during this interim analysis.

🧬 The Phase 2 portion of the trial evaluated two different dose levels, with higher efficacy noted at the lower dose compared to the higher one.

🩺 Disease control rate (DCR) reached 100% in the patient population evaluated, indicating strong stabilization of the disease for all responders.

Bullish Signals
  • Pumitamig demonstrated robust and consistent antitumor activity in first-line non-small cell lung cancer across all PD-L1 expression levels, including TPS < 1%, TPS 1-49%, and TPS ≥ 50%.
  • The lower dose of pumitamig plus chemotherapy achieved the highest confirmed objective response rates, with 63.6% in non-squamous subtypes and an exceptional 72.7% in squamous subtypes.
  • At the interim analysis, the drug combination showed a perfect disease control rate (DCR) of 100% across all evaluated patients.
  • Pumitamig exhibited a manageable safety profile with only a low discontinuation rate of 9.3%, driven by four treatment-related adverse events in 48.8% of patients.
  • The company is advancing the asset through a comprehensive global Phase 3 development program, with two additional pivotal Phase 3 trials currently enrolling alongside the ROSETTA Lung-02 trial.
  • BioNTech and Bristol Myers Squibb are accelerating development with a broad registrational plan covering multiple disease stages, including new combination trials with antibody-drug conjugates.
Risk Factors
  • The interim data from the ROSETTA Lung-02 trial was presented only as a rapid oral abstract at the ASCO Annual Meeting, indicating that full publication has not yet occurred.
  • Although the confirmed objective response rate reached 100% for patients with TPS ≥ 50%, this represents a very narrow subgroup compared to broader populations where efficacy is lower (47.6%).
  • Bleeding events occurred in 20.9% of patients, which poses safety concerns given that the mechanism involves inhibiting VEGF-A, typically associated with vascular risks.
  • Grade ≥ 3 treatment-related adverse events were reported in 48.8% of patients, representing a significant burden for advanced cancer patients already facing toxicity from chemotherapy.
  • Four patients (9.3%) discontinued treatment due to pumitamig-related adverse events, raising questions about long-term tolerability at the interim analysis stage.
Full Analysis
BioNTech and Bristol Myers Squibb have announced encouraging interim Phase 2 data from the global ROSETTA Lung-02 clinical trial for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator. The combination of pumitamig with chemotherapy demonstrated robust antitumor activity in patients with previously untreated advanced non-small cell lung cancer (NSCLC) across all evaluated dose levels and PD-L1 expression subtypes. At the interim analysis with an April 13, 2026 data cut-off, treatment showed high efficacy regardless of tumor subtype or programmed death-ligand 1 status. Specifically, among response-evaluable patients, pumitamig plus chemotherapy achieved a confirmed objective response rate (cORR) of 57.1% in non-squamous NSCLC and 68.4% in squamous NSCLC at the interim analysis. Higher response rates were observed at the lower dose level, with a cORR of 63.6% for non-squamous NSCLC and 72.7% for squamous NSCLC. The efficacy was consistent across patients with less than 1%, between 1-49%, and greater than or equal to 50% PD-L1 tumor proportion score (TPS), reaching 100% response in the TPS ≥ 50 group at the lower dose. Furthermore, the treatment demonstrated a disease control rate of 100% and showed a manageable safety profile with Grade 3 treatment-related adverse events reported in 23.3% of patients attributed to pumitamig, leading to discontinuation in only 9.3% of cases. The companies are advancing a comprehensive global Phase 3 development program for pumitamig in NSCLC following these positive results. In addition to the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, two additional global Phase 3 trials are underway, including ROSETTA Lung-201 comparing pumitamig to durvalumab following concurrent chemoradiation in unresectable stage III NSCLC and ROSETTA Lung-202 evaluating pumitamig against pembrolizumab as a first-line treatment for advanced PD-L1 ≥ 50% NSCLC. These results support the continued investigation of pumitamig's potential to set a new standard of care by enhancing anti-tumor responses in one of oncology's most challenging indications.